Our mission is to treat hearing loss.

Otologic Pharmaceutics, Inc. (OPI) is a company committed to developing treatments for acute and chronic hearing loss to reduce the incidence and severity of permanent hearing disorders.

OPI’s program NHPN-1010, an oral medication to treat acute hearing loss, has successfully completed a Phase I clinical trial. Initial research focuses on NHPN-1010 as a treatment for Noise Induced Hearing Loss. OPI’s program OPI-001, an innovative treatment for acute and chronic hearing loss through the regeneration of sensory hair cells, has been awarded a Congressionally Directed Medical Research Programs grant from the Department of Defense to fund further preclinical research and development.